Höhn AK, Brambs CE, Hiller GGR, May D, Schmoeckel E, Horn L-C. 2020 WHO Classification of Female Genital Tumors, Geburtshilfe Frauenheilkd, vol. 81, no. 10, pp. 1145–1153, Oct. 2021. https://doi.org/10.1055/a-1545-4279

Semczuk A, Gogacz M, Semczuk-Sikora A, Jóźwik M, Rechberger T. The putative role of TP53 alterations and p53 expression in borderline ovarian Tumors - Correlation with clinicopathological features and prognosis: A Mini-Review. J Cancer. Aug. 2017;8(14):2684–91. https://doi.org/10.7150/jca.19691.

Priya C, Kumar S, Kumar L. Borderline ovarian tumours: An update, Indian J Med Paediatr Oncol, vol. 29, no. 2, pp. 19–27, Apr. 2008, https://doi.org/10.4103/0971-5851.51427

Du Bois A et al. May., Borderline tumours of the ovary: A cohort study of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Study Group, European Journal of Cancer, vol. 49, no. 8, pp. 1905–1914, 2013, https://doi.org/10.1016/j.ejca.2013.01.035

Colombo N et al. May., ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease, Annals of Oncology, vol. 30, no. 5, pp. 672–705, 2019, https://doi.org/10.1093/annonc/mdz062

Høgdall C, Thomsen L, Lundvall L, Christensen I, Lajer H, Schnack T, Bjørn S. Classification of ovarian cancer surgery facilitates treatment decisions in a gynecological multidisciplinary team. Int J Gynecol Cancer. 2017;27(2):382–9. https://doi.org/10.1097/IGC.0000000000000876.

Article  PubMed  Google Scholar 

Fischerova D, Zikan M, Dundr P, Cibula D. Diagnosis, Treatment, and Follow-Up of Borderline Ovarian Tumors, The Oncologist, vol. 17, no. 12, pp. 1515–1533, Dec. 2012, https://doi.org/10.1634/theoncologist.2012-0139

Olsen CM et al. Apr., Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium, Endocr Relat Cancer, vol. 20, no. 2, p. 10.1530/ERC-12–0395, 2013, https://doi.org/10.1530/ERC-12-0395

Tsuboyama T, et al. MRI of borderline epithelial ovarian tumors: pathologic correlation and diagnostic challenges. Radiographics. Nov. 2022;42(7):2095–111. https://doi.org/10.1148/rg.220068.

Fotopoulou C et al. Sept., The Value of Serum CA125 in the Diagnosis of Borderline Tumors of the Ovary, International Journal of Gynecological Cancer, vol. 25, no. 7, pp. 1248–1252, 2015, https://doi.org/10.1097/IGC.0000000000000476

Shih KK, Garg K, Soslow RA, Chi DS, Abu-Rustum NR, Barakat RR. Accuracy of frozen section diagnosis of ovarian borderline tumor, Gynecol Oncol, vol. 123, no. 3, pp. 517–521, Dec. 2011, https://doi.org/10.1016/j.ygyno.2011.08.013

Winter WE, Kucera PR, Rodgers W, McBroom JW, Olsen C, Maxwell GL. Surgical staging in patients with ovarian tumors of low malignant potential, Obstet Gynecol, vol. 100, no. 4, pp. 671–676, Oct. 2002, https://doi.org/10.1016/s0029-7844(02)02171-3

Hacker KE, Uppal S, Johnston C. Principles of treatment for Borderline, micropapillary Serous, and Low-Grade ovarian cancer. J Natl Compr Canc Netw. Sept. 2016;14(9):1175–82. https://doi.org/10.6004/jnccn.2016.0124.

Tropé CG, Kaern J, Davidson B. Borderline ovarian tumours. Best Pract Res Clin Obstet Gynaecol. June 2012;26(3):325–36. https://doi.org/10.1016/j.bpobgyn.2011.12.006.

Du Bois A, Trillsch F, Mahner S, Heitz F, Harter P. Management of borderline ovarian tumors. Ann Oncol. Apr. 2016;27:i20–2. https://doi.org/10.1093/annonc/mdw090.

Camatte S et al. Sept., Lymph node disorders and prognostic value of nodal involvement in patients treated for a borderline ovarian tumor: an analysis of a series of 42 lymphadenectomies, J Am Coll Surg, vol. 195, no. 3, pp. 332–338, 2002, https://doi.org/10.1016/s1072-7515(02)01250-4

Song T, et al. The role of appendectomy in patients with mucinous borderline ovarian tumors. Eur J Obstet. Oct. 2018;229:112–6. https://doi.org/10.1016/j.ejogrb.2018.06.034. & Gynecology and Reproductive Biology

Morice P, et al. Prognostic factors for patients with advanced stage serous borderline tumours of the ovary. Ann Oncol. Apr. 2003;14(4):592–8. https://doi.org/10.1093/annonc/mdg173.

Fauvet R, Boccara J, Dufournet C, Poncelet C, Daraï E. Laparoscopic management of borderline ovarian tumors: results of a French multicenter study, Ann Oncol, vol. 16, no. 3, pp. 403–410, Mar. 2005, https://doi.org/10.1093/annonc/mdi083

Morice P, Uzan C, Fauvet R, Gouy S, Duvillard P, Darai E. Borderline ovarian tumour: pathological diagnostic dilemma and risk factors for invasive or lethal recurrence. Lancet Oncol. Mar. 2012;13(3):e103–115. https://doi.org/10.1016/S1470-2045(11)70288-1.

Gershenson DM. Management of borderline ovarian tumours. Best Pract Res Clin Obstet Gynaecol. May 2017;41:49–59. https://doi.org/10.1016/j.bpobgyn.2016.09.012.

Della Corte L, et al. The challenging management of borderline ovarian tumors (BOTs) in women of childbearing age. Front Surg. Aug. 2022;9. https://doi.org/10.3389/fsurg.2022.973034.

Morice P, et al. Fertility-sparing treatment and follow-up in patients with cervical cancer, ovarian cancer, and borderline ovarian tumours: guidelines from ESGO. ESHRE ESGE Lancet Oncol. Nov. 2024;25(11):e602–10. https://doi.org/10.1016/S1470-2045(24)00262-6.

Carbonnel M, et al. Serous borderline ovarian tumor Diagnosis, management and fertility preservation in young women. JCM. Sept. 2021;10:4233. https://doi.org/10.3390/jcm10184233.

Song T, et al. Histologic distribution of borderline ovarian tumors worldwide: a systematic review. J Gynecol Oncol. Jan. 2013;24(1):44–51. https://doi.org/10.3802/jgo.2013.24.1.44.

Slomovitz BM, et al. A comparative analysis of 57 serous borderline tumors with and without a noninvasive micropapillary component. Am J Surg Pathol. May 2002;26(5):592–600. https://doi.org/10.1097/00000478-200205000-00005.

Bonadio RC, De Siqueira Santos AG, Estevez-Diz MDP. Borderline ovarian tumors: a review of its biology, molecular profile, and management, Brazilian Journal of Oncology, vol. 20, no. CP, pp. 2526-8732.20230437, Mar. 2024, https://doi.org/10.5935/2526-8732.20230437

Sadlecki P, Grzanka D, Grabiec M. Testing for NRAS Mutations in Serous Borderline Ovarian Tumors and Low-Grade Serous Ovarian Carcinomas, Dis Markers, vol. 2018, p. 1497879, Feb. 2018. https://doi.org/10.1155/2018/1497879

Emmanuel C, et al. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-Mutant tumors and identifies NRAS as an oncogenic driver. Clin Cancer Res. Dec. 2014;20:6618–30. https://doi.org/10.1158/1078-0432.CCR-14-1292.

Hada T, et al. Prognostic similarity between ovarian mucinous carcinoma with expansile invasion and ovarian mucinous borderline tumor. Med (Baltim). Aug. 2021;100:e26895. https://doi.org/10.1097/MD.0000000000026895.

Morice P, Gouy S, Leary A. Mucinous Ovarian Carcinoma, N Engl J Med, vol. 380, no. 13, pp. 1256–1266, Mar. 2019, https://doi.org/10.1056/NEJMra1813254

Kurman RJ. Blaustein’s pathology of the female genital tract. Springer Science & Business Media; 2013.

IARC Publications Website - WHO Classification of Tumours. Accessed: Feb. 19, 2025. [Online]. Available: https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours

Kurata Y, et al. Differentiation of seromucinous borderline tumor from serous borderline tumor on MR imaging. Magn Reson Med Sci. Oct. 2017;17(3):211–7. https://doi.org/10.2463/mrms.mp.2017-0055.

Hw S, Ma R, Ae SS, Bm R, Rj K. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas. Am J Surg Pathol. Dec. 2002;26(12). https://doi.org/10.1097/00000478-200212000-00001.

Zheng R, Heller DS. Borderline Brenner tumor: A review of the literature. Arch Pathol Lab Med. Oct. 2019;143(10):1278–80. https://doi.org/10.5858/arpa.2018-0285-RS.

De Cecio R et al. Dec., Borderline Brenner tumor of the ovary: a case report with immunohistochemical and molecular study, J Ovarian Res, vol. 7, no. 1, Art. no. 1, 2014, https://doi.org/10.1186/s13048-014-0101-7

Seong SJ, Kim DH, Kim MK, Song T. Controversies in borderline ovarian tumors. J Gynecol Oncol. 2015;26(4):343. https://doi.org/10.3802/jgo.2015.26.4.343.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nayyar P, Lakhwani A, Goel P, Kr, Pande, Kumar K. Management of borderline ovarian Tumors—Still a Gray zone. Indian J Surg Oncol. Dec. 2017;8(4):607–14. https://doi.org/10.1007/s13193-017-0697-3.

Tinelli R, Tinelli A, Tinelli FG, Cicinelli E, Malvasi A Conservative surgery for borderline ovarian tumors: a review. Gynecol Oncol Jan. 2006;100(1):185–91. https://doi.org/10.1016/j.ygyno.2005.09.021.

Article  Google Scholar